230 related articles for article (PubMed ID: 19070991)
41. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
[TBL] [Abstract][Full Text] [Related]
42. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
43. Insight and recovery in schizophrenic patients.
Cannavò D; Minutolo G; Battaglia E; Aguglia E
Int J Psychiatry Clin Pract; 2016; 20(2):83-90. PubMed ID: 26902557
[TBL] [Abstract][Full Text] [Related]
44. Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France.
Gasquet I; Haro JM; Tcherny-Lessenot S; Chartier F; Lépine JP
Eur Psychiatry; 2008 Oct; 23(7):491-6. PubMed ID: 18573640
[TBL] [Abstract][Full Text] [Related]
45. [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study].
Wolter A; Preuss U; Krischke N; Wong JW; Langosch JM; Zimmermann J
Fortschr Neurol Psychiatr; 2010 Aug; 78(8):468-74. PubMed ID: 20694939
[TBL] [Abstract][Full Text] [Related]
46. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
47. [The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample].
Ciudad A; Prieto L; Olivares JM; Montejo AL; Ros S; Novick D;
Actas Esp Psiquiatr; 2004; 32(4):227-35. PubMed ID: 15232752
[TBL] [Abstract][Full Text] [Related]
48. [Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years].
Haro JM; Ciudad A; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
Actas Esp Psiquiatr; 2008; 36(4):187-96. PubMed ID: 18461495
[TBL] [Abstract][Full Text] [Related]
49. Regional differences in treatment response and three year course of schizophrenia across the world.
Novick D; Haro JM; Hong J; Brugnoli R; Lepine JP; Bertsch J; Karagianis J; Dossenbach M; Alvarez E
J Psychiatr Res; 2012 Jul; 46(7):856-64. PubMed ID: 22575332
[TBL] [Abstract][Full Text] [Related]
50. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of remission and recovery in schizophrenia in the Czech Republic.
Prikryl R; Kholova M; Kucerova HP; Ceskova E
Compr Psychiatry; 2013 Oct; 54(7):1111-6. PubMed ID: 23810077
[TBL] [Abstract][Full Text] [Related]
52. The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study.
Helldin L; Kane JM; Hjärthag F; Norlander T
Schizophr Res; 2009 Nov; 115(1):67-73. PubMed ID: 19666215
[TBL] [Abstract][Full Text] [Related]
53. Clinical recovery in first-episode psychosis.
Wunderink L; Sytema S; Nienhuis FJ; Wiersma D
Schizophr Bull; 2009 Mar; 35(2):362-9. PubMed ID: 18990715
[TBL] [Abstract][Full Text] [Related]
54. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study.
San L; Ciudad A; Alvarez E; Bobes J; Gilaberte I
Eur Psychiatry; 2007 Nov; 22(8):490-8. PubMed ID: 17904337
[TBL] [Abstract][Full Text] [Related]
55. Schizophrenia Outpatient Health Outcomes study: twelve-month findings.
Novick D; Ascher-Svanum H; Haro JM; Bertsch J; Takahashi M
Pragmat Obs Res; 2012; 3():27-40. PubMed ID: 27774015
[TBL] [Abstract][Full Text] [Related]
56. Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community.
Bernardo M; Cañas F; Herrera B; García Dorado M
Rev Psiquiatr Salud Ment; 2017; 10(3):149-159. PubMed ID: 27291833
[TBL] [Abstract][Full Text] [Related]
57. Remission and recovery during the first outpatient year of the early course of schizophrenia.
Ventura J; Subotnik KL; Guzik LH; Hellemann GS; Gitlin MJ; Wood RC; Nuechterlein KH
Schizophr Res; 2011 Oct; 132(1):18-23. PubMed ID: 21764563
[TBL] [Abstract][Full Text] [Related]
58. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.
Lambert M; Schimmelmann BG; Naber D; Schacht A; Karow A; Wagner T; Czekalla J
J Clin Psychiatry; 2006 Nov; 67(11):1690-7. PubMed ID: 17196047
[TBL] [Abstract][Full Text] [Related]
59. Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study.
Cuyún Carter GB; Milton DR; Ascher-Svanum H; Faries DE
BMC Psychiatry; 2011 Aug; 11():143. PubMed ID: 21871092
[TBL] [Abstract][Full Text] [Related]
60. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
